Search
lofexidine (Lucemyra)
Indications:
- opioid withdrawal
Mechanism of action:
- inhibits release of norepinephrine
- reduces symptoms of diarrhea, nausea/vomiting, anxiety, & malaise associated with opioid withdrawal [2]
Interactions
drug adverse effects of adrenergic receptor agonists
General
alpha-2 adrenergic receptor agonist
Database Correlations
PUBCHEM correlations
References
- US WorldMeds. Mar 27, 2018,
FDA Advisory Committee Votes in Favor of LUCEMYRA
(lofexidine) for the Mitigation of Opioid Withdrawal Symptoms.
https://www.prnewswire.com/news-releases/fda-advisory-committee-votes-in-favor-of-lucemyra-lofexidine-for-the-mitigation-of-opioid-withdrawal-symptoms-300620526.html
- FDA Advisory Committees
Briefing Information for the March 27, 2018 Meeting of the
Psychopharmacologic Drugs Advisory Committee (PDAC).
https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/ucm602415.htm
- Brooks M
FDA Approves First Nonopioid Drug for Opioid Withdrawal.
Medscape - May 16, 2018.
https://www.medscape.com/viewarticle/896736
- FDA News Release. May 16, 2018
FDA approves the first non-opioid treatment for management
of opioid withdrawal symptoms in adults.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607884.htm